This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Phenol oily injection 5%

Updated 2 Feb 2023 | Haemorrhoidal sclerosants


Sterile solution for injection containing 5% w/v phenol

Drugs List

  • phenol 5% oily injection
  • Therapeutic Indications


    Scleropathy of haemorrhoidal veins

    Analgesic sclerosing agent in the treatment of internal haemorrhoids.



    2 to 3 ml injected at the base of the haemorrhoid.

    Several sites may be injected but the maximum total at any one time is 10 ml.


    (See Dosage; Adult).


    For injection into the submucosal layer at the base of the haemorrhoid only.


    Children under 18 years

    Precautions and Warnings


    Contains almond oil
    Only for haemorrhoid submucosal injection
    Protect surrounding skin
    To avoid side effects care should be taken when choosing the injection site
    Avoid deep or misplaced injections

    Avoid application to surrounding skin, since serious complications can arise from misplaced injections. Extreme care should be taken when choosing the injection site.

    Phenol is available in different formulations. Healthcare professionals should take extra care to ensure that the correct formulation is being used. Confusion between different strength and preparations has resulted in patient harm.

    Complications during therapy include local ulceration and sterile abscess formation. These can be serious following a misplaced injection (e.g. prostatic abscess).

    Pregnancy and Lactation


    Manufacturers advise that Phenol oily injection 5% is not recommended in pregnancy.

    Safety in pregnancy has not been established and the effects on the foetus are unknown.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Manufacturers advise that phenol oily injection 5% is not recommended in breastfeeding.

    There are no adequate and well-controlled studies or case reports on its use topically or in breastfeeding women (Hale 2014).

    It is not known whether or not phenol is excreted in human milk. The safety of this drug regarding breastfeeding has not been established yet.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Hypersensitivity reactions
    Irritation (localised)
    Necrosis (injection site)
    Necrotising fasciitis
    Prostatic abscess
    Rectal pain/discomfort
    Retroperitoneal sepsis
    Urinary incontinence


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: February 2017

    Reference Sources

    Joint Formulary Committee. British National Formulary. 72nd ed. London: BMJ Group and Pharmaceutical Press; 2016.

    Martindale: The Complete Drug Reference. 38th Edition. London: Brayfield A (ed). Pharmaceutical Press; 2014.

    Medications and Mothers' Milk, Sixteenth Edition (2014) Hale, T and Rowe, H, Hale Publishing, Plano, Texas.

    Summary of Product Characteristics: Oily Phenol Injection 5% BP. Martindale Pharma Ltd. Revised June 2010.

    National Patient Safety Agency - National Reporting and Learning Service: Wrong strength phenol: signal. Ref number: 1162D. 26th Feb 2010.
    Last accessed: 16th February 2017.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.